Far East Africa, also known as the "Thalassemia Belt." 2, 3 In Pakistan, around 5000-9000 children are born with β-thalassemia every year, having an estimated carrier rate of 5%-7%, with 9.8 million carriers in the total population. 4, 5 β° thalassemia is characterized by the total deficiency of HbA (α 2 β 2 ), due to the inheritance of two β° thalassemia alleles (compound heterozygous or homozygous states).This is termed as β-thalassemia major, in which patients present with symptoms requiring transfusion dependency beginning from the first half of postnatal life. 6 On the other end of the thalassemia spectrum is thalassemia minor(trait) in which there is presence of single β-thalassemia allele, β + or β°, in which there is increased Hb A 2 (α 2 δ 2 ) without transfusion requirement. 7 The third type, thalassemia intermedia, is also due to the inheritance of two β-thalassemia alleles as in thalassemia major, but this condition is neither as severe as thalassemia major nor as mild as thalassemia trait. 7, 8 Such patients might present with anemia and usually require infrequent blood transfusion after the first 2 years of life. 6 The thalassemia intermedia genotypically and clinically is a heterogeneous group of blood disorder. The severity could lie from the nonsymptomatic carrier state to the severe symptomatic state dependent on blood transfusion. 6, 9, 10 Approximately 5%-10% of thalassemia intermedia patients could live without requiring any blood transfusion.
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The presence of the primary genetic mutations modifies the disease behavior and hence presents in a less severe form, due to which the primary genetic mutations could be acknowledged as a primary genetic modifier. 12 In this study, we have investigated the primary and secondary genetic modifiers, to develop a laboratory finding by creating the commonest genetic combinations seen among thalassemia intermedia patients. This study could help to broadly quantify the diversity of thalassemia intermedia patients in the subcontinent, specifically Pakistan, and might help to draw evidence based guidelines for identifying the cohort patients who can be managed optimally without blood transfusion. This will also help for appropriate genetic counseling to the families in this region.
| MATERIAL AND ME THODS
This cross-sectional study analyzed a total of 315 patients, affected by thalassemia intermedia, attending the National insti- thalassemia major patients were recruited as well. Approval for this study was granted by medical ethics committee of the institute. The procedure was explained, and an informed consent was obtained from each individual, and from parents of individuals younger than 18 years of age.
Patients were selected, based on their thalassemia-specific clinical presentation (Hb = 3-10gm/dL, age of presentation >2 years for intermedia while transfusion dependency beginning from <2 years for thalassemia major) in addition to Hb Electrophoresis and DNA mutation. 13 Thalassemia intermedia and major cases having at least one of the genetic mutations or Xmn1 polymorphism missing from its data were removed during the analysis for genetic combination, of which 85 cases of intermedia and three cases of major were removed.
| Laboratory parameters

| Hematological analysis
On the basis of the complete blood count (CBC) investigation were obtained in ethylenediaminetetraacetic acid (EDTA) tubes and performed on Sysmex XE-2100 hematology analyzer (Kobe, Japan 
| Biochemical analysis
At the time of presentation, serum creatinine, SGPT, and ferritin level were performed. The serum sample was collected in a red top vacutainer. For serum creatinine and SGPT, the test was per- 
| Molecular analysis
DNA was extracted from the whole blood, using a DNA Purification kit (Genra system USA). 
| Clinical parameters
Age of 1st transfusion and Hb level (g/dL), transfusion frequency (No. of Packed RBCs/year), mean volume (mL) of blood transfusion during whole life, spleen, and liver size (cm) were noted.
| Statistical method
STATA version 11.1was used for data analysis.
| RE SULTS
Out of 307 thalassemia intermedia patients, 52% were males with mean age of 5.9 years. Table 1 shows the comparison of laboratory and clinical parameters of thalassemia intermedia and major patients. Table 2 shows that among the two groups: IVSI-5 and IVSI-1 are more prevalent.
Hence, just signifying the frequency of single mutations toward a genetic diagnosis of thalassemia intermedia could be misleading. Table 3 identifies the commonest mutational combinations with the presence or absence of Xmn1 polymorphism toward the prediction of thalassemia intermedia. Table 4 shows significant results (P-value<0.001) for the presence of Xmn-1 polymorphism in both groups.
| D ISCUSS I ON
The aim of this study was to identify patients with thalassemia intermedia on the basis of primary and secondary modifiers in Pakistan.
It was found that thalassemia intermedia patients are likely to have particular types of mutations of the beta-globin gene locus. Furthermore, it has also demonstrated that the Xmn-1 mutation in the gamma-globin gene promoter is associated with thalassemia intermedia patients at a higher rate in either homozygous or heterozygous state than those with thalassemia major.
TA B L E 1 Thalassemia intermedia laboratory and clinical parameters
In the developing world scenario, a significant number of thalassemia cases are frequented. However, if the timely diagnosis for thalassemia intermedia is not performed there remains a high probability of being started on continuous blood transfusion therapy immediately, which could lead to transfusion-associated complications, that is iron overload, Hepatitis B, Hepatitis C and HIV, and as per studies 13%-70% patients are prone toward these infections. 14, 15 Keeping in view this background, specific primary and secondary genetic characteristics were investigated in this study toward the prediction of thalassemia intermedia. The genetic mutations, that is, IVSI-5 and Cd 30 are the mutations that have been found to play a major role in affecting the phenotypic presentation of thalassemia patients and make them behave like intermedia. So the role of genetic mutations in terms of genetic modifiers has been discussed.
| Clinico hematological characteristics
| Genetic combinations
As the presence of certain gene mutation (IVS1-5,IVS1-1, Fr-8-9)
was not significant toward the prediction of thalassemia intermedia, the mutations were then analyzed for the possible different genetic combinations (homozygous and heterozygous with or without Xmn-1 polymorphism), which led to a more specific picture of the genetic mutations. This indicated that the presence of
Xmn-1 polymorphism with certain mutational combinations was significant.
IVSI-5 and IVSI-I, either in homozygous or heterozygous condi-
tions, were found to be prevalent among thalassemia intermedia only when Xmn-1 polymorphism was present. IVSI-5 in homozygous state without Xmn-1 polymorphism was seen at a lower percentage (38%) and with the presence of Xmn-1 polymorphism was seen at a higher percentage (92%) within thalassemia intermedia patients (Table 3 ). This clearly highlights the fact that the presence of Xmn-1 does play a significant role as a secondary genetic modifier among thalassemia intermedia patients.
For mutation Cd 30, in homozygous state, with either Xmn-1 polymorphism present or absent was found to be exceedingly prevalent within the thalassemia intermedia cohort, hence, not giving any significance to the presence or absence of Xmn-1 polymorphism. This specific mutation (Cd 30), however, will be required to be studied in more detail with a larger sample size. Similarly, the homozygous Uncharacterized mutations with Xmn-1 polymorphism present or absent had higher proportion of thalassemia intermedia.
In heterozygous state, Uncharacterized mutations were found to be abundant in thalassemia intermedia when found in combination with IVSI-5.
The above discussion gives a prediction toward identifying thalassemia intermedia genetically on the basis of the mutations present in heterozygous or homozygous state, with or without Xmn-1 polymorphism. This could help reaching an early diagnosis of intermedia and would help in preventing unnecessary blood transfusions among patients who are wrongfully labeled as thalassemia major (Figure 1 ).
| Secondary genetic modifiers
The Xmn1 polymorphism, which acts as a secondary genetic modifier, was found in 58.6% of the thalassemia intermedia patients in our study. It has been seen that the Xmn1 polymorphism contributes toward ameliorating the phenotype as well. 26 The thalassemia intermedia patients were compared to thalassemia major patients, which showed significant results (P-value <0.001) for the presence of Xmn-1 Polymorphism which is shown in Table 4 . This justifies that the presence of Xmn-1 polymorphism creates an impact toward the hematological finding of the patients, specifically within the thalassemia major cohort, which clearly shows that within the thalassemia major patients, the presence of Xmn-1 polymorphism is drastically less, due to which such patients might not be able to respond to hemoglobin augmenting agents therapy. 
| CON CLUS ION
The pivotal extract of this study is the significant presence of Xmn1polymorphism among thalassemia intermedia patients within
Pakistan. The various genetic combinations discussed could be utilized toward an early detection for thalassemia intermedia or ruling out thalassemia major, which eventually could help prevent unnecessary blood transfusions. The results could form a basis toward identifying other genetic modifiers for beta-thalassemia.
However, the strengths of this study are compromised by limitations. This study has focused exclusively on the findings of the genetic mutations rather than looking into the clinical and hematological characteristics of the thalassemia intermedia and thalassemia major patients. A need for further such studies with comparison of the clinical and hematological characteristics of the patients is required towards developing a more precise genetic diagnosis for thalassemia intermedia with a larger sample. This study could, however, act as a platform for further research as per this approach.
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